Classical Hodgkin Lymphoma in Children and Adolescents — Relapsed or Refractory Disease
This protocol addresses children and adolescents aged 18 years or younger with classical Hodgkin lymphoma whose disease has relapsed after prior treatment or failed to respond to initial therapy.
Clinical Scenario
The patient is a child or adolescent (age 18 years or younger) with classical Hodgkin lymphoma. The disease is either relapsed — it has come back after treatment — or refractory — it did not respond to the initial treatment given.
Treatment Approach
Re-induction therapy is considered for this population. Several structured combination regimens are available, with the appropriate choice guided by patient-specific factors and clinical context — the full protocol specifies which options apply and how they are sequenced.
References
- Treatments for Children and Adolescents with Relapsed or Refractory Classical Hodgkin Lymphoma.
- Treatment options for children and adolescents whose disease has relapsed (come back after treatment) or is refractory (did not respond to initial treatment).
- Re-Induction Therapy Options (in alphabetical order): Brentuximab vedotin + bendamustine, Brentuximab vedotin + gemcitabine, Brentuximab vedotin + nivolumab, DHAP (dexamethasone, cytarabine, cisplatin), GV (gemcitabine, vinorelbine), IGEV (ifosfamide, gemcitabine, vinorelbine), IV (ifosfamide, vinorelbine).